|
1.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
2.
|
An JY, Cheong JH, Hyung WJ and Noh SH:
Recent evolution of surgical treatment for gastric cancer in Korea.
J Gastric Cancer. 11:1–6. 2011. View Article : Google Scholar
|
|
3.
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
4.
|
Sakuramoto S, Sasako M, Yamaguchi T, et
al: Adjuvant chemotherapy for gastric cancer with S-1, an oral
fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Denko NC: Hypoxia, HIF1 and glucose
metabolism in the solid tumour. Nat Rev Cancer. 8:705–713. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Park MJ, Lee WJ, Lim HK, Park KW, Choi JY
and Kim BT: Detecting recurrence of gastric cancer: the value of
FDG PET/CT. Abdom Imaging. 34:441–447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Weber WA, Petersen V, Schmidt B, et al:
Positron emission tomography in non-small-cell lung cancer:
prediction of response to chemotherapy by quantitative assessment
of glucose use. J Clin Oncol. 21:2651–2657. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Wieder HA, Brucher BL, Zimmermann F, et
al: Time course of tumor metabolic activity during
chemoradiotherapy of esophageal squamous cell carcinoma and
response to treatment. J Clin Oncol. 22:900–908. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Madhok BM, Yeluri S, Perry SL, Hughes TA
and Jayne DG: Targeting glucose metabolism: an emerging concept for
anti-cancer therapy. Am J Clin Oncol. 34:628–635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Kawamura T, Kusakabe T, Sugino T, et al:
Expression of glucose transporter-1 in human gastric carcinoma:
association with tumor aggressiveness, metastasis, and patient
survival. Cancer. 92:634–641. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Noguchi Y, Marat D, Saito A, et al:
Expression of facilitative glucose transporters in gastric tumors.
Hepatogastroenterology. 46:2683–2689. 1999.PubMed/NCBI
|
|
12.
|
Kaelin WG Jr and Thompson CB: Q&A:
cancer: clues from cell metabolism. Nature. 465:562–564. 2010.
|
|
13.
|
Egawa-Takata T, Endo H, Fujita M, et al:
Early reduction of glucose uptake after cisplatin treatment is a
marker of cisplatin sensitivity in ovarian cancer. Cancer Sci.
101:2171–2178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Warburg O: On respiratory impairment in
cancer cells. Science. 124:269–270. 1956.PubMed/NCBI
|
|
15.
|
Noske A, Kaszubiak A, Weichert W, et al:
Specific inhibition of AKT2 by RNA interference results in
reduction of ovarian cancer cell proliferation: increased
expression of AKT in advanced ovarian cancer. Cancer Lett.
246:190–200. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Surowiak P, Materna V, Denkert C, et al:
Significance of cyclooxygenase 2 and MDR1/P-glycoprotein
coexpression in ovarian cancers. Cancer Lett. 235:272–280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Kim JW and Dang CV: Multifaceted roles of
glycolytic enzymes. Trends Biochem Sci. 30:142–150. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Holness MJ and Sugden MC: Regulation of
pyruvate dehydrogenase complex activity by reversible
phosphorylation. Biochem Soc Trans. 31:1143–1151. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Bowker-Kinley M and Popov KM: Evidence
that pyruvate dehydrogenase kinase belongs to the ATPase/kinase
superfamily. Biochem J. 344:47–53. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Popov KM: Regulation of mammalian pyruvate
dehydrogenase kinase. FEBS Lett. 419:197–200. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Papandreou I, Cairns RA, Fontana L, Lim AL
and Denko NC: HIF-1 mediates adaptation to hypoxia by actively
downregulating mitochondrial oxygen consumption. Cell Metab.
3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Kim JW, Tchernyshyov I, Semenza GL and
Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: a metabolic switch required for cellular adaptation to
hypoxia. Cell Metab. 3:177–185. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Stacpoole PW: Review of the pharmacologic
and therapeutic effects of diisopropylammonium dichloroacetate
(DIPA). J Clin Pharmacol J New Drugs. 9:282–291. 1969.PubMed/NCBI
|
|
24.
|
Michelakis ED, Sutendra G, Dromparis P, et
al: Metabolic modulation of glioblastoma with dichloroacetate. Sci
Transl Med. 2:31ra342010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sun RC, Fadia M, Dahlstrom JE, Parish CR,
Board PG and Blackburn AC: Reversal of the glycolytic phenotype by
dichloro-acetate inhibits metastatic breast cancer cell growth in
vitro and in vivo. Breast Cancer Res Treat. 120:253–260. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Wong JY, Huggins GS, Debidda M, Munshi NC
and De Vivo I: Dichloroacetate induces apoptosis in endometrial
cancer cells. Gynecol Oncol. 109:394–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Cao W, Yacoub S, Shiverick KT, et al:
Dichloroacetate (DCA) sensitizes both wild-type and over expressing
Bcl-2 prostate cancer cells in vitro to radiation. Prostate.
68:1223–1231. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tong J, Xie G, He J, Li J, Pan F and Liang
H: Synergistic antitumor effect of dichloroacetate in combination
with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol.
2011:7405642011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Bonnet S, Archer SL, Allalunis-Turner J,
et al: A mitochondria-K+ channel axis is suppressed in cancer and
its normalization promotes apoptosis and inhibits cancer growth.
Cancer Cell. 11:37–51. 2007.
|
